Trump Links Fed Rate Cuts to Iran War as Inflation Pressures Persist

Nitish Kishor | 20 May 2026

The Dollar's Yield-Driven Strength Carries Structural Risks the Market Is Underpricing

Ankur Sharma | 20 May 2026

Lowe's Beats Q1 Estimates as Spring and Pro Demand Offset Stubborn DIY Weakness

Key Highlights

Nitish Kishor | 20 May 2026

Drug Discovery as a Machine Learning Problem: When Algorithms Make Pharmaceuticals Obsolete

Key HighlightsTraditional drug discovery takes 12 years and costs over $2 billion per approved drug, with a 90% clinical trial failure rate that AI is systematically addressing.AlphaFold solved the protein folding problem in structural biology, unlocking decades of compounding scientific progress that will fundamentally …

Nitish Kishor | 20 May 2026

Skye Bioscience Advances Obesity Study After Positive Safety Review of Nimacimab

Skye Advances Higher-Dose Obesity Trial

Nitish Kishor | 20 May 2026

Arm Holdings (NASDAQ: ARM) Stock Surges as Nvidia Earnings Hype Fuels AI Semiconductor Rally

Key Highlights

Nitish Kishor | 20 May 2026

Immunovant, Inc. (NASDAQ: IMVT) Stock Analysis: IMVT-1402 Emerges as the Company’s Defining Growth Driver

Key Highlights

Nitish Kishor | 20 May 2026

Jupiter Neurosciences, Inc. (NASDAQ: JUNS) Stock Analysis: Psychedelic Therapeutics Strategy Gains Momentum

Key Highlights

Nitish Kishor | 20 May 2026

ImmunityBio, Inc. (NASDAQ: IBRX) Stock Analysis: FDA Review Expands ANKTIVA Commercial Opportunity

Key Highlights

Nitish Kishor | 20 May 2026

Annovis Bio Launches Public Offering to Advance Late-Stage Alzheimer’s Programme

Annovis Bio Strengthens Capital Position

Nitish Kishor | 20 May 2026

News

Trump Links Fed Rate Cuts to Iran War as Inflation Pressures Persist

The Dollar's Yield-Driven Strength Carries Structural Risks the Market Is Underpricing

Lowe's Beats Q1 Estimates as Spring and Pro Demand Offset Stubborn DIY Weakness

Drug Discovery as a Machine Learning Problem: When Algorithms Make Pharmaceuticals Obsolete

Skye Bioscience Advances Obesity Study After Positive Safety Review of Nimacimab

Arm Holdings (NASDAQ: ARM) Stock Surges as Nvidia Earnings Hype Fuels AI Semiconductor Rally

Immunovant, Inc. (NASDAQ: IMVT) Stock Analysis: IMVT-1402 Emerges as the Company’s Defining Growth Driver

Jupiter Neurosciences, Inc. (NASDAQ: JUNS) Stock Analysis: Psychedelic Therapeutics Strategy Gains Momentum

ImmunityBio, Inc. (NASDAQ: IBRX) Stock Analysis: FDA Review Expands ANKTIVA Commercial Opportunity

Annovis Bio Launches Public Offering to Advance Late-Stage Alzheimer’s Programme

Latest News

Broadway's $1.9 Billion Season: A New Era of Experiential Spending

Advanced Micro Devices (NASDAQ:AMD) Chases Nvidia as the AI Chip Race Heats Up

Walmart's Retail Strength and Digital Growth Keep the Consumer Giant in Focus

AstraZeneca (NYSE:AZN) Stock Outlook: Oncology Pipeline Drives Growth and Valuation Debate

Visa (NYSE:V) Stock Outlook: Payments Volume and Cross-Border Growth Drive Steady Earnings

Exxon Mobil Stock Outlook: Cash Flow Strength Anchors Energy Giant Amid Oil Price Volatility